Advocates Must Press the CDC to Enforce its PrEP Patents in Order to End HIV as an Epidemic
Statement / Press • 2019TAG statement calling for advocates to stand with PrEP4All in demanding CDC enforce its PrEP patents.
TAG and Allies Rally for Affordable HIV Prevention Medication
Statement / Press • 2019On Monday February 18, TAG, some of our allies, and a number of elected officials attended a rally in New York City calling on the National Institutes of Health to exercise its march-in rights and break Gildead’s patent on Truvada.
Public Comment on USPSTF Draft Recommendations for PrEP and HIV Screening
Letters • 2019The US Preventive Services Task Force (USPSTF) recently released draft recommendations regarding HIV screening for all Americans ages 15-65, including pregnant women, and pre-exposure prophylaxis (PrEP) for individuals highly vulnerable to HIV infection.
Treatment Action Group Statement on the President’s Fiscal Year 2020 Budget Proposal
Statement / Press • 2019Treatment Action Group (TAG) opposes the President's FY 2020 budget proposal, which makes a mockery of the administration's purported strategy to end AIDS in the United States over the next decade.
A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy
Letters • 2019October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they’re concerned that it doesn’t apply to all countries. Read/Download the comment
Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson
Statement / Press • 2019Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.
Eight HIV/AIDS Research, Policy, and Advocacy Organizations File an Amici Curiae Brief in Staley v. Gilead – Background and Next Steps
Statement / Press • 2019On October 25, 2019, eight HIV/AIDS research, policy, and advocacy organizations filed an amicus brief in the U.S. District Court, in San Francisco, CA, in support of the plaintiffs in Staley v. Gilead.
TAG Comment in Response to Proposed Rulemaking: Visas: Ineligibility Based on Public Charge Grounds
Letters • 2019As an organization dedicated to ensuring equitable access to critical health services to individuals and communities affected by HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV), Treatment Action Group (TAG) strongly opposes the proposed changes regarding “public charge,” published in the Federal Register on October 11, 2019 (the proposed rule).
ANEA Response to Guardian Article on Gov. Rick Scott’s Rejection of $70 Million in Federal Funding to Fight Florida’s HIV/AIDS Crisis
Statement / Press • 2019The Act Now End AIDS coalition is deeply troubled by the contents of Ben Ryan’s September 11 Guardian article “'Rick Scott had us on lockdown:' how Florida said no to $70m for HIV crisis." The article, which reflects four years of investigative journalism by Ryan with additional reporting by Noah Pransky, paints a detailed picture of how Florida’s then-governor, Rick Scott, refused Medicaid expansion and federal dollars to fight the epidemic from 2015-2017
Treatment Action Group Joins Collective Call Denouncing the Trump Administration’s Dangerous Finalized Anti-Immigrant Rule
Statement / Press • 2019Treatment Action Group (TAG) strongly opposes the administration’s finalized rule “Inadmissibility on Public Charge Grounds.” This rule, which goes into effect on October 15, 2019, dangerously expands the definition of immigrants who are ineligible for admission into the U.S. or adjustment of status to include those who seek basic public services for health, nutrition, and housing.